Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature

BACKGROUND. Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor, is currently approved for the treatment of progressive pancreatic neuroendocrine tumors (NETs). Although promising, only scattered data, often from nondedicated studies, are available for extrapancreatic NETs. PATIENTS A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Faggiano, Antongiulio, Malandrino, Pasqualino, Modica, Roberta, Agrimi, Daniela, Aversano, Maurizio, Bassi, Vincenzo, Giordano, Ernesto A., Guarnotta, Valentina, Logoluso, Francesco A., Messina, Erika, Nicastro, Vincenzo, Nuzzo, Vincenzo, Sciaraffia, Marcello, Colao, Annamaria
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2016
Assuntos:
Endocrinology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943387/
https://ncbi.nlm.nih.gov/pubmed/27053503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0420
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados